All In Biotech

Drug Trial Radar · NCT04824092

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL)

Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 899 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

899

Actual

Start

May 11, 2021

Primary completion

Sep 1, 2026

Study completion Nov 1, 2027

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Apr 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL

Conditions

  • Diffuse Large B-cell Lymphoma

Interventions

  • TafasitamabDrug

    Tafasitamab IV infusion will be administered as per the schedule specified in the respective arm.

  • LenalidomideDrug

    Lenalidomide PO will be administered as per the schedule specified in the respective arm.

  • RituximabDrug

    Rituximab IV infusion will be administered as per the schedule specified in the respective arm.

  • CyclophosphamideDrug

    Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.

  • DoxorubicinDrug

    Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.

  • VincristineDrug

    Vincristine IV infusion will be administered as per the schedule specified in the respective arm.

  • PrednisoneDrug

    Prednisone PO will be administered as per the schedule specified in the respective arm.

  • Tafasitamab placeboDrug

    0.9% saline solution IV infusion will be administered as per the schedule specified in the respective arm.

  • Lenalidomide placeboDrug

    Placebo matching to lenalidomide PO will be administered as per the schedule specified in the respective arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFS-INVTime frame: Time from date of randomization until Progressive Disease or death from any cause. In this trial, the primary endpoint is PFS as assessed by the investigator (up to 43 months)

Locations

307 sites in 29 countries. Site status is shown where the registry gives one.

  • MorphoSys Research Site

    Daphne, Alabama

  • MorphoSys Research Site

    Anaheim, California

  • MorphoSys Research Site

    Clovis, California

  • MorphoSys Research Site

    Fullerton, California

  • MorphoSys Research Site

    Harbor City, California

  • MorphoSys Research Site

    Los Angeles, California

  • MorphoSys Research Site

    San Diego, California

  • MorphoSys Research Site

    Whittier, California

  • MorphoSys Research Site

    Aurora, Colorado

  • MorphoSys Research Site

    Jacksonville, Florida

  • MorphoSys Research Site

    Honolulu, Hawaii

  • MorphoSys Research Site

    Wichita, Kansas

  • MorphoSys Research Site

    Lexington, Kentucky

  • MorphoSys Research Site

    Louisville, Kentucky

  • MorphoSys Research Site

    Baltimore, Maryland

  • MorphoSys Research Site

    Bethesda, Maryland

  • MorphoSys Research Site

    Columbia, Maryland

  • MorphoSys Research Site

    Detroit, Michigan

  • MorphoSys Research Site

    Minneapolis, Minnesota

  • MorphoSys Research Site

    Rochester, Minnesota

  • MorphoSys Research Site

    Kansas City, Missouri

  • MorphoSys Research Site

    Lebanon, New Hampshire

  • MorphoSys Research Site

    Florham Park, New Jersey

  • MorphoSys Research Site

    Buffalo, New York

  • MorphoSys Research Site

    Rochester, New York

  • MorphoSys Research Site

    Canton, Ohio

  • MorphoSys Research Site

    Cincinnati, Ohio

  • MorphoSys Research Site

    Eugene, Oregon

  • MorphoSys Research Site

    Danville, Pennsylvania

  • MorphoSys Research Site

    Chattanooga, Tennessee

  • MorphoSys Research Site

    Germantown, Tennessee

  • MorphoSys Research Site

    Nashville, Tennessee

  • MorphoSys Research Site

    Austin, Texas

  • MorphoSys Research Site

    Bedford, Texas

  • MorphoSys Research Site

    Denison, Texas

  • MorphoSys Research Site

    Fort Worth, Texas

  • MorphoSys Research Site

    Houston, Texas

  • MorphoSys Research Site

    McAllen, Texas

  • MorphoSys Research Site

    Tyler, Texas

  • MorphoSys Research Site

    Ogden, Utah

Showing 40 of 307 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.